Boston Scientific

Corporate brand

Unclaimed Request correction

A global medical-device company specializing in minimally invasive technologies for interventional medicine.

Last updated October 13, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Boston Scientific Corporation is a United States-based multinational medical-device manufacturer whose products are used in minimally invasive procedures. The company serves a broad range of interventional specialties, including interventional cardiology, electrophysiology, peripheral and vascular intervention, neuromodulation, neurovascular care, endoscopy, urology, gynecology, oncology, cardiac surgery and related fields. Its business is centered on devices that allow physicians to diagnose, treat or manage disease through catheters, implants, energy systems and other less-invasive techniques rather than conventional open surgery. The company traces its origins to Medi-Tech, a medical-products venture associated with inventor Itzhak Bentov. Medi-Tech developed steerable catheter technology, including an angiography catheter introduced in 1969. John Abele joined the business during this formative period and later partnered with Pete Nicholas to create a broader corporate platform for growth in interventional medicine. Boston Scientific was formed in 1979 in Watertown, Massachusetts, as a holding company for Medi-Tech and subsequently expanded through acquisitions and operating-company combinations. During the 1980s, the company broadened its capabilities in gastrointestinal and pulmonary devices, urology, vascular filters and cardiac measurement systems. The combination of Mansfield Scientific, Microvasive and Medi-Tech in 1988 created a more integrated Boston Scientific business. Its 1992 initial public offering placed the company on the New York Stock Exchange and supplied a public-market base for subsequent research, acquisitions and international expansion. Boston Scientific became particularly associated with coronary intervention through the TAXUS drug-eluting stent, which received European and other international approvals in 2003 and United States FDA approval in 2004. The device helped establish the company as a major participant in the drug-eluting-stent market. The 2006 acquisition of Guidant, shared between Boston Scientific and Abbott Laboratories, substantially expanded the company’s cardiac rhythm and cardiovascular capabilities, although the integration later involved restructuring and job reductions. Since the 2010s, Boston Scientific has pursued a portfolio strategy built around both internal development and acquisitions. It added or strengthened businesses in structural heart therapy, electrophysiology, cardiac mapping, implantable defibrillation, endoscopy, urology, women’s health, pain management, peripheral intervention and surgical energy. Acquisitions such as Cameron Health, Atritech, EndoChoice, Symetis, BTG, Preventice Solutions, Baylis Medical and Axonics extended its clinical reach and added new platforms. The company has also divested or discontinued selected activities when they no longer fit its strategy. Boston Scientific’s present identity is that of a diversified, innovation-led medical-technology company. Its products include coronary and peripheral intervention systems, cardiac rhythm and electrophysiology devices, implantable defibrillation systems, neurostimulation platforms, endoscopic devices, urological and gynecological instruments, and technologies for pain and vascular treatment. The company operates internationally and is incorporated in Delaware, while its principal headquarters are in Marlborough, Massachusetts. Its competitive positioning rests on clinical specialization, physician-oriented procedural technology, regulatory expertise, acquisitions and a large global commercial infrastructure.

History

Boston Scientific emerged from the Boston-area medical-technology ecosystem surrounding Medi-Tech. Itzhak Bentov and Dan Singer developed engineering and research activities that led to a steerable angiography catheter, while John Abele became an important early commercial and strategic participant. Abele later partnered with Pete Nicholas, and together they organized Boston Scientific in 1979 as a holding company intended to support Medi-Tech and growth in interventional medicine. The company expanded quickly through acquisitions. Kimray Medical Associates, later Mansfield Scientific, added vena cava filters and cardiac-output technology. Endo-Tech, later associated with Microvasive, extended the portfolio into gastrointestinal and pulmonary products, while Van-Tec added urological devices. Mansfield Scientific, Microvasive and Medi-Tech were brought together in 1988, creating a more unified operating platform. Manufacturing and international distribution also developed during this period. Boston Scientific went public in 1992 with an offering of 23.5 million shares, with the United States shares listed on the New York Stock Exchange. In the second half of the 1990s, the company used acquisitions to build capabilities in intravascular imaging, cardiovascular intervention, urology, vascular grafts, electrophysiology and specialty manufacturing. In 1998 it restated certain 1997 and 1998 results because of business irregularities in its Japanese subsidiary. The acquisition of Target Therapeutics in 2001 broadened the company into neurovascular intervention. The TAXUS drug-eluting coronary stent became one of its best-known products after international approval in 2003 and FDA approval in 2004. Boston Scientific also expanded through transactions involving Advanced Bionics, Advanced Stent Technologies, CryoVascular, Rubicon Medical and other specialist developers. Some programs were later discontinued or divested, including the Boston Scientific Santa Rosa endovascular-aortic-repair business. The 2006 Guidant transaction was a major turning point. It brought substantial cardiac-device capabilities into Boston Scientific, although the company later reorganized its heart-rhythm operations and eliminated approximately 1,300 positions in 2010. The post-merger period also included portfolio reshaping, including the sale of fluid-management and venous-access businesses and the creation of Navilyst Medical from divested operations. From 2010 onward, Boston Scientific concentrated on growth areas such as atrial-fibrillation treatment, left-atrial-appendage closure, implantable defibrillation, renal and peripheral intervention, endoscopy, structural heart, women’s health, urology and neuromodulation. Cameron Health added the EMBLEM subcutaneous defibrillator. Atritech contributed the WATCHMAN platform, while acquisitions and investments involving electrophysiology mapping, ablation, structural-heart valves, endoscopy, pain therapy and vascular intervention continued to reshape the portfolio. The company’s acquisition program accelerated in the late 2010s and early 2020s. BTG expanded specialty intervention; Preventice added mobile cardiac monitoring; Lumenis added surgical technologies; Farapulse added pulsed-field ablation; Baylis Medical strengthened electrophysiology access and structural-heart products; and Relievant and Axonics expanded pain and urology offerings. Boston Scientific also made manufacturing and supply-chain investments in the United States. Its current business combines internal research, regulatory and commercial capabilities with acquisitions of focused medical-technology companies. The company remains headquartered in Marlborough, Massachusetts, operates internationally and is publicly traded under the symbol BSX.

2024
Axonics acquisition announced
[1]Boston Scientificen.wikipedia.org
Boston Scientific announced a proposed acquisition of Axonics for approximately $3.7 billion.
2021
Preventice, Lumenis, Farapulse and Baylis expansion
[1]Boston Scientificen.wikipedia.org
A series of transactions strengthened mobile cardiac monitoring, surgical technology, pulsed-field ablation and electrophysiology access.
2018
BTG acquisition announced
[1]Boston Scientificen.wikipedia.org
Boston Scientific announced the acquisition of BTG for approximately $4.2 billion.
2012
Cameron Health acquisition
[1]Boston Scientificen.wikipedia.org
The transaction brought the EMBLEM subcutaneous implantable cardioverter-defibrillator into the portfolio.
2006
Guidant acquisition
[1]Boston Scientificen.wikipedia.org
Boston Scientific acquired Guidant, adding major cardiac rhythm and cardiovascular businesses.
2004
TAXUS stent receives United States approval
[1]Boston Scientificen.wikipedia.org
The TAXUS drug-eluting coronary stent received FDA approval and became a signature Boston Scientific product.
2001
Target Therapeutics acquisition
[1]Boston Scientificen.wikipedia.org
The acquisition expanded Boston Scientific’s position in neurovascular intervention.
1992
Initial public offering
[1]Boston Scientificen.wikipedia.org
Boston Scientific completed an IPO of 23.5 million shares, with its United States shares listed on the New York Stock Exchange.
1988
Medi-Tech, Microvasive and Mansfield are combined
[1]Boston Scientificen.wikipedia.org
The combination created a broader integrated Boston Scientific operating platform spanning several medical-device specialties.
1979
Boston Scientific is formed
[1]Boston Scientificen.wikipedia.org
Boston Scientific was established in Watertown, Massachusetts, as a holding company for Medi-Tech and a vehicle for expansion in interventional medicine.

Products and positioning

A high-technology medical-device brand focused on minimally invasive procedures, clinical innovation and integrated interventional-care platforms.

Interventional cardiology · 2003
TAXUS drug-eluting stent
TAXUS is a coronary drug-eluting stent designed to open narrowed arteries while delivering an antiproliferative drug intended to reduce the risk of restenosis. Its international approvals beginning in 2003 and United States approval in 2004 made it one of Boston Scientific’s most visible cardiovascular product lines and an important contributor to the company’s position in coronary intervention.
Structural heart · 2011
WATCHMAN
WATCHMAN is a catheter-delivered left atrial appendage closure system. It is designed for selected patients with non-valvular atrial fibrillation as an alternative approach to reducing stroke risk associated with clot formation in the left atrial appendage. The platform came to Boston Scientific through the acquisition of Atritech.
Cardiac rhythm management · 2012
EMBLEM S-ICD
EMBLEM is a subcutaneous implantable cardioverter-defibrillator developed from Cameron Health. Unlike a conventional transvenous ICD, the system places the defibrillation lead beneath the skin rather than inside the heart and vasculature, providing a minimally invasive option for selected patients at risk of sudden cardiac death.
Neuromodulation
Vercise
Vercise is a deep-brain-stimulation platform used in neuromodulation procedures. It is part of Boston Scientific’s broader portfolio of implantable stimulation technologies for neurological and movement-related conditions and reflects the company’s expansion beyond cardiovascular intervention.
Electrophysiology · 2021
FARAPULSE
FARAPULSE is a pulsed-field ablation platform for electrophysiology procedures. It uses non-thermal energy intended to create controlled ablation lesions in the treatment of selected cardiac arrhythmias. Boston Scientific acquired the remaining interest in Farapulse in 2021 after previously holding a stake.

Controversies

2026
Boston Scientific discloses cyberattack disrupting global operations
Boston Scientific said on Wednesday that a cyberattack affecting some of its information-technology systems has caused global disruptions and limited access to certain information systems and business applications supporting its operations, including its ability to process and ship customer orders. The company said it does not yet know the full scope and nature of the breach, including operational and financial impacts, and is working with cybersecurity experts to assess and contain the threat and restore affected systems, without a timeline for full restoration.
Source
2026
FDA classifies Boston Scientific ENROUTE device recall as Class I
The FDA classified a recall of certain Boston Scientific ENROUTE Transcarotid Neuroprotection System and ENROUTE NPS Plus devices as Class I, the most serious type, following reports of arterial sheath tip separation during use. Boston Scientific had sent the initial letter to affected customers on July 9, 2026.
Source
2021
Jury finds Nevro infringed two Boston Scientific patents
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
Source
2010
Improper physician payment enforcement action
The United States Department of Justice fined Boston Scientific $600,000 after the company paid an Army doctor to use its devices and recommend them to other physicians. The matter concerned improper inducement and raised compliance concerns about interactions between medical-device companies and clinicians.
Source

2024
Acquire AxonicsM&A
Background
The transaction was intended to strengthen Boston Scientific’s urology and neuromodulation businesses.
Action taken
Boston Scientific announced an agreement to acquire Axonics for approximately $3.7 billion.
Aftermath
The reported transaction would expand Boston Scientific’s sacral-neuromodulation offering, subject to the applicable closing conditions.
Announced acquisition value. Approximately $3.7 billion (2024)
Source
2018
Acquire BTGM&A
Background
Boston Scientific sought to broaden its interventional-medicine portfolio and add BTG’s specialist technologies.
Action taken
The company announced a proposed acquisition of BTG for approximately $4.2 billion.
Aftermath
BTG became part of Boston Scientific’s interventional and specialty portfolio.
Announced acquisition value. Approximately $4.2 billion (2018)
Source
2006
Acquire GuidantM&A
Background
Boston Scientific sought to expand substantially in cardiac rhythm management and cardiovascular devices through the purchase of a major competitor.
Action taken
It completed the acquisition of Guidant for approximately $27.2 billion, while Abbott Laboratories acquired other Guidant assets.
Aftermath
The deal transformed the company’s cardiovascular scale but was followed by integration and restructuring, including the later elimination of approximately 1,300 heart-rhythm positions.
Acquisition value. Approximately $27.2 billion (2006)
Source

Recent events

2027-01-01
Boston Scientific appoints Joe Fitzgerald as EVP and Chief Operating Officer, effective 1 January 2027[6]波士顿科学任命Joe Fitzgerald为执行副总裁兼首席运营官，2027年1月1日生效healthcare-digital.com
Reported: 2026-10-08
Boston Scientific appointed Joe Fitzgerald as its next Executive Vice President and Chief Operating Officer, effective 1 January 2027, re-establishing the COO position. Fitzgerald, currently EVP of the Cardiovascular division, will oversee global operations, commercial business units and regions as the medtech manufacturer pursues international expansion.
Unconfirmed
Boston Scientific restructures operating model into three reportable clinical segments[6]波士顿科学任命Joe Fitzgerald为执行副总裁兼首席运营官，2027年1月1日生效healthcare-digital.com
Reported: 2026-10-08
Boston Scientific announced a restructuring of its operating model into three reportable segments — Interventional Therapies under Lance Bates, Rhythm Solutions under Nick Spadea-Anello and MedSurg under Stephen Morse — shifting from product-centric business units to a model aligned with clinical delivery pathways, while consolidating investments as it targets US$500m in annual run-rate cost savings by the end of 2029.
2026-08-26
FDA classifies Boston Scientific ENROUTE device recall as Class I[4]FDA classifies Boston Scientific ENROUTE device recall as Class Itechtimes.com
Reported: 2026-08-27
The FDA classified a recall of certain Boston Scientific ENROUTE Transcarotid Neuroprotection System and ENROUTE NPS Plus devices as Class I, the most serious type, following reports of arterial sheath tip separation during use. Boston Scientific had sent the initial letter to affected customers on July 9, 2026.
2026-08-26
Boston Scientific discloses cyberattack disrupting global operations and shipments[7]波士顿科学披露网络攻击扰乱全球运营与发货finance.yahoo.com
Reported: 2026-08-26
Boston Scientific disclosed on Wednesday that a cyberattack detected the previous day is disrupting its global operations, including its ability to process and ship customer orders.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
2026-08-26
Boston Scientific discloses cyberattack disrupting global operations[3]Boston Scientific discloses cyberattack disrupting global operationsmorningstar.com
Reported: 2026-08-26
Boston Scientific said on Wednesday that a cyberattack affecting some of its information-technology systems has caused global disruptions and limited access to certain information systems and business applications supporting its operations, including its ability to process and ship customer orders. The company said it does not yet know the full scope and nature of the breach, including operational and financial impacts, and is working with cybersecurity experts to assess and contain the threat and restore affected systems, without a timeline for full restoration.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
2026-08-25
Boston Scientific discloses cybersecurity incident disrupting global operations[8]波士顿科学披露网络安全事件导致全球运营中断thestar.com.my
Reported: 2026-08-26
Boston Scientific said on Wednesday that a cybersecurity incident detected on August 25 disrupted global operations, including some information systems used to process and ship customer orders. The company activated incident-response procedures and is working with third-party cybersecurity specialists to investigate and contain the threat; it said the full scope and nature of the incident have not yet been determined and it has not determined whether the incident is reasonably likely to have a material impact on its business.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
2022-02-15
Boston Scientific finalizes Baylis Medical acquisition[9]波士顿科学完成对 Baylis Medical 的收购wbjournal.com
Reported: 2022-02-15
Boston Scientific finalized its acquisition of Quebec-based Baylis Medical Co. Inc. on Tuesday.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
2021-11-01
Jury finds Nevro infringed two Boston Scientific patents[5]Jury finds Nevro infringed two Boston Scientific patentsprnewswire.com
Reported: 2021-11-01
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
2021-06
Boston Scientific elects David Wichmann to its board[10]波士顿科学选举大卫·威奇曼加入董事会wbjournal.com
Reported: 2021-07-01
Boston Scientific announced that David Wichmann had been elected to its board of directors, effective immediately.
2021-01-22
FDA approves Boston Scientific Vercise Genus system[11]美国FDA批准波士顿科学Vercise Genus系统wbjournal.com
Reported: 2021-01-26
The FDA approved Boston Scientific’s fourth-generation Vercise Genus Deep Brain Stimulation System. The system is intended to provide symptom relief for Parkinson’s disease.

Showing the 10 most recent.

Sources25 sources

Cite this profile: Cite the canonical profile. /brand-wiki/boston-scientific · Editorial policy · How profiles are compiled